基石薬業に関するコメント

CStone Pharmaceuticals' lower P/S ratio is due to its perceived limited future growth. Analysts' inferior revenue outlook contributes to its low P/S, making a significant share price rise unlikely soon.

CStone Pharmaceuticals' low P/S ratio is due to its poor revenue outlook. The market anticipates limited growth, paying less for the stock. These conditions form a barrier for the share price.

HBM gets health boost from drug licensing deals
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...

The company's lack of profit over the last year prompts caution despite recent insider purchase showing confidence. Caution urged before investing in CStone Pharmaceuticals, despite insiders seeing potential value.